Save up to 50% on select online and hands-on training bundles!
The FDA’s recent approval of Eli Lilly’s Foundayo (orforglipron) adds another once-daily oral GLP-1 option for providers and patients. This approval follows the December 2025 approval of Novo Nordisk’s once-daily oral Wegovy pill (semaglutide 25 mg), the first oral GLP-1 approved for chronic weight management in adults. For the first time, providers now have two FDA-approved oral GLP-1 medications for obesity to discuss with patients — and they are meaningfully different.
What you will learn in this article:
While both medications target the GLP-1 receptor, their underlying chemistry differs significantly. The Wegovy pill is a large peptide molecule (semaglutide), similar to its injectable counterpart. Because peptide drugs such as semaglutide are degraded in the digestive tract, the Wegovy pill must be taken under specific fasting conditions to achieve adequate absorption.
In contrast, Foundayo is a small nonpeptide molecule. As a small-molecule GLP-1 agonist, it does not have fasting or water-intake restrictions and can be taken at any time of day, with or without food.
In the Phase 3 ATTAIN-1 trial, patients taking the highest dose of Foundayo (36 mg once daily) achieved a mean weight loss of about 11.2% to 12.4% over 72 weeks, depending on whether analyses included all randomized participants or focused on those who remained on treatment. The trial enrolled 3,127 participants without diabetes. Patients on the 6 mg and 12 mg doses lost a mean of 7.5% and 8.4% respectively, compared to 2.1% in the placebo group.
For the Wegovy pill, the Phase 3 OASIS 4 trial demonstrated a mean weight loss of about 13.6% in the overall trial population and up to 16.6% among adherent patients over 64 weeks. The trial enrolled 307 participants without diabetes, with a placebo group achieving approximately 2.4% mean weight loss.
Both manufacturers are utilizing pricing strategies to capture market share, which presents opportunities for practices focusing on comprehensive weight management.
According to Eli Lilly’s approval announcement, Foundayo will be available starting at $149 per month for the lowest dose for patients paying out of pocket, with eligible commercially insured patients potentially paying as little as $25 per month with a savings card. As reported by Managed Healthcare Executive, Novo Nordisk offers a similar introductory Wegovy pill price starting at $149 per month through its direct-to-consumer and savings-offer programs for lower doses, with higher-dose tiers expected to cost more later in the year.
For providers, the availability of these oral options — particularly at competitive self-pay price points — reinforces the need to position your practice’s value beyond simply writing a prescription. Patients can increasingly access the medication itself; what they need from a physician is the structured support program (such as ketogenic or intermittent fasting plans, and strength-building protocols) that ensures the weight loss is healthy and sustainable.
Is Foundayo more effective than the Wegovy pill?
There is currently no direct head-to-head trial comparing the two medications. Trial data shows significant weight loss for both, but the studies were conducted separately with different patient populations and timeframes.
How does the dosing differ between the two?
The Wegovy pill must be taken on an empty stomach with a small amount of water, followed by a 30-minute wait before eating or drinking. Foundayo can be taken at any time of day without food or water restrictions.
What are the common side effects?
Both medications share the common gastrointestinal side effects typical of the GLP-1 class, including nausea, diarrhea, vomiting, and constipation.
Are these medications covered by insurance?
Coverage varies widely by plan. Both manufacturers offer copay savings programs for eligible commercially insured patients, and self-pay options typically start around $149 per month for the lowest doses. Savings programs generally exclude government-insured patients and have additional eligibility and duration limits.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.